Regeneron, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren from TD Cowen maintained a Buy rating on the stock and has a $800.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tyler Van Buren has given his Buy rating due to a combination of factors that highlight Regeneron’s strong financial performance and future growth potential. The company reported a significant 23% earnings per share (EPS) beat, driven by increased revenue and effective cost management. This strong performance is attributed to the growth of Eylea HD, which continues to show robust demand despite competitive pressures and pricing challenges.
Additionally, Regeneron’s Dupixent (Dupi) is performing exceptionally well, with annualized sales exceeding $19 billion and maintaining its leadership in new and total prescriptions. The anticipated contributions from its COPD and CSU indications further bolster its growth outlook. Moreover, the potential benefits from the Sanofi development balance payoff in 2026/2027 are not fully appreciated by the market, providing additional upside potential for the stock.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $767.00 price target.